Uremic solutes and risk of end-stage renal disease in type 2 diabetes: Metabolomic study

Kidney International

Volumn 85, Issue 5, 2014, Pages 1214-1224

  Niewczas, Monika A ^a,b   Sirich, Tammy L ^c   Mathew, Anna V ^d   Skupien, Jan ^a,b,e   Mohney, Robert P ^f   Warram, James H ^a,b   Smiles, Adam ^a   Huang, Xiaoping ^g   Walker, Walker ^a   Byun, Jaeman ^d   Karoly, Edward D ^f   Kensicki, Elizabeth M ^f   Berry, Gerard T ^b,g   Bonventre, Joseph V ^b,h   Pennathur, Subramaniam ^d   Meyer, Timothy W ^c   Krolewski, Andrzej S ^a,b  

^a Joslin Diabetes Institute   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e JAGIELLONIAN UNIVERSITY   (Poland)

^f METABOLON INC   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h Brigham and Womens Hospital   (United States)

Author keywords

Diabetic nephropathy; End stage renal disease; Metabolomic study; Uremic toxins

Indexed keywords

ACYLCARNITINE; ALBUMIN; AMINO ACID DERIVATIVE; CARBOHYDRATE; ESSENTIAL AMINO ACID; HEMOGLOBIN A1C; LIPID; NUCLEOTIDE; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD LEVEL; CARBOHYDRATE BLOOD LEVEL; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE BLOOD LEVEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; UREMIA; URINARY ALBUMIN EXCRETION; URINARY EXCRETION; AGED; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; KIDNEY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; TIME; UNITED STATES;

AGED; AMINO ACIDS, ESSENTIAL; BIOLOGICAL MARKERS; BOSTON; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MASS SPECTROMETRY; METABOLOMICS; MIDDLE AGED; TIME FACTORS; UREMIA;

EID: 84899913633     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.497     Document Type: Article

References (77)

1. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2010.
2. Wang JH, Byun J, Pennathur S. Analytical approaches to metabolomics and applications to systems biology. Semin Nephrol 2010; 30: 500-511.
3. Portilla D, Schnackenberg L, Beger RD. Metabolomics as an extension of proteomic analysis: study of acute kidney injury. Semin Nephrol 2007; 27: 609-620.
4. Dehaven CD, Evans AM, Dai H et al. Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminform 2010; 2: 9.
5. Evans AM, Dehaven CD, Barrett T et al. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009; 81: 6656-6667.
6. Ohta T, Masutomi N, Tsutsui N et al. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol 2009; 37: 521-535.
7. Duranton F, Cohen G, De Smet R et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23: 1258-1270.
8. Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007; 357: 1316-1325.
9. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943.
10. Rhee EP, Souza A, Farrell L et al. Metabolite profiling identifies markers of uremia. J Am Soc Nephrol 2010; 21: 1041-1051.
11. Aronov PA, Luo FJ, Plummer NS et al. Colonic contribution to uremic solutes. J Am Soc Nephrol 2011; 22: 1769-1776.
12. Eloot S, Schepers E, Barreto DV et al. Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol 2011; 6: 1266-1273.
13. Meyer TW, Hostetter TH. Uremic solutes from colon microbes. Kidney Int 2012; 81: 949-954.
14. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999; 42: 263-285.
15. Vaidya VS, Niewczas MA, Ficociello LH et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetylbeta-D- glucosaminidase. Kidney Int 2011; 79: 464-470.
16. Cano NJ, Fouque D, Leverve XM. Application of branched-chain amino acids in human pathological states: renal failure. J Nutr 2006; 136: 299S-307S.
17. Garibotto G, Sofia A, Saffioti S et al. Amino acid and protein metabolism in the human kidney and in patients with chronic kidney disease. Clin Nutr 2010; 29: 424-433.
18. Goek ON, Doring A, Gieger C et al. Serum metabolite concentrations and decreased GFR in the general population. Am J Kidney Dis 2012; 60: 197-206.
19. Wang TJ, Larson MG, Vasan RS et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011; 17: 448-453.
20. Zhang H, Saha J, Byun J et al. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295: F1071-F1081.
21. Zhao T, Zhang H, Zhao T et al. Intrarenal metabolomics reveals the association of local organic toxins with the progression of diabetic kidney disease. J Pharm Biomed Anal 2012; 60: 32-43.
22. Makinen VP, Soininen P, Forsblom C et al. Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum. MAGMA 2006; 19: 281-296.
23. Makinen VP, Tynkkynen T, Soininen P et al. Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J Proteome Res 2012; 11: 1782-1790.
24. van der Kloet FM, Tempels FW, Ismail N et al. Discovery of early-stage biomarkers for diabetic kidney disease using MS-based metabolomics (FinnDiane study). Metabolomics 2012; 8: 109-119.
25. Zhang J, Yan L, Chen W et al. Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-MS system. Anal Chim Acta 2009; 650: 16-22.
26. Niewczas MA, Gohda T, Skupien J et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012; 23: 507-515.
27. Floegel A, Drogan D, Wang-Sattler R et al. Reliability of serum metabolite concentrations over a 4-month period using a targeted metabolomic approach. PLoS One 2011; 6: e21103.
28. Milligan GV. A review of Monte Carlo tests of cluster analysis. Multivariate Behav Res 1981; 16: 379-407.
29. Xia J, Wishart DS. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc 2011; 6: 743-760.
30. Itoh Y, Ezawa A, Kikuchi K et al. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem 2012; 403: 1841-1850.
31. Meijers BK, Claes K, Bammens B et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5: 1182-1189.
32. Nicholson JK, Holmes E, Kinross J et al. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-1267.
33. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
34. Boudonck KJ, Mitchell MW, Nemet L et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol 2009; 37: 280-292.
35. Clements RS Jr, DeJesus PV Jr, Winegrad AI. Raised plasma-myoinositol levels in uraemia and experimental neuropathy. Lancet 1973; 1: 1137-1141.
36. Arner RJ, Prabhu KS, Thompson JT et al. Myo-inositol oxygenase: molecular cloning and expression of a unique enzyme that oxidizes myo-inositol and D-chiro-inositol. Biochem J 2001; 360: 313-320.
37. Nayak B, Kondeti VK, Xie P et al. Transcriptional and post-translational modulation of myo-inositol oxygenase by high glucose and related pathobiological stresses. J Biol Chem 2011; 286: 27594-27611.
38. Berry GT, Mallee JJ, Kwon HM et al. The human osmoregulatory Naþ/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome Genomics 1995; 25: 507-513.
39. Mallee JJ, Atta MG, Lorica V et al. The structural organization of the human Naþ/myo-inositol cotransporter (SLC5A3) gene and characterization of the promoter. Genomics 1997; 46: 459-465.
40. Wang S, Mitu GM, Hirschberg R. Osmotic polyuria: an overlooked mechanism in diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 2167-2172.
41. Kennington AS, Hill CR, Craig J et al. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1990; 323: 373-378.
42. Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med 2010; 16: 543-552.
43. Daughaday WH, Larner J. The renal excretion of inositol in normal and diabetic human beings. J Clin Invest 1954; 33: 326-332.
44. Ziyadeh FN, Simmons DA, Snipes ER et al. Effect of myo-inositol on cell proliferation and collagen transcription and secretion in proximal tubule cells cultured in elevated glucose. J Am Soc Nephrol 1991; 1: 1220-1229.
45. Bartnicki P, Zbrog Z, Baj Z et al. Myoinositol may be a factor in uremic immune deficiency. Clin Nephrol 1997; 47: 197-201.
46. Charette M, Gray MW. Pseudouridine in RNA: what, where, how, and why. IUBMB Life 2000; 49: 341-351.
47. Seidel A, Brunner S, Seidel P et al. Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control. Br J Cancer 2006; 94: 1726-1733.
48. Daniewska-Michalska D, Motyl T, Gellert R et al. Efficiency of hemodialysis of pyrimidine compounds in patients with chronic renal failure. Nephron 1993; 64: 193-197.
49. Gerrits GP, Monnens LA, De Abreu RA et al. Disturbances of cerebral purine and pyrimidine metabolism in young children with chronic renal failure. Nephron 1991; 58: 310-314.
50. Niwa T, Takeda N, Yoshizumi H. RNA metabolism in uremic patients: accumulation of modified ribonucleosides in uremic serum. Technical note. Kidney Int 1998; 53: 1801-1806.
51. Huang S, Mahanta N, Begley TP et al. Pseudouridine monophosphate glycosidase: a new glycosidase mechanism. Biochemistry 2012; 51: 9245-9255.
52. Bernert JT Jr., Bell CJ, Guntupalli J et al. Pseudouridine is unsuitable as an endogenous renal clearance marker. Clin Chem 1988; 34: 1011-1017.
53. Vaziri ND, Freel RW, Hatch M. Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol 1995; 6: 1313-1317.
54. Anzai N, Kanai Y, Endou H. New insights into renal transport of urate. Curr Opin Rheumatol 2007; 19: 151-157.
55. Ficociello LH, Rosolowsky ET, Niewczas MA et al. High-normal serum uric acid increases risk of early declining renal function in type 1 diabetes: results of 6-year follow-up. Diabetes Care 2010; 33: 1337-1343.
56. Chiang CK, Tanaka T, Nangaku M. Dysregulated oxygen metabolism of the kidney by uremic toxins: review. J Ren Nutr 2012; 22: 77-80.
57. Kawakami T, Inagi R, Wada T et al. Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. Am J Physiol Renal Physiol 2010; 299: F568-F576.
58. Ahn SY, Bhatnagar V. Update on the molecular physiology of organic anion transporters. Curr Opin Nephrol Hypertens 2008; 17: 499-505.
59. Wang L, Sweet DH. Renal organic anion transporters (SLC22 Family): expression, regulation, roles in toxicity, and impact on injury and disease. AAPS J 2012; 15: 53-69.
60. Nelson RG, Williams RC, Hanson RL et al. Prediction of diabetic nephropathy by urine metabolomic profiling. J Am Soc Nephrol 2010; 21: 566A.
61. Monica TA, Mac LM, Muller A et al. Altered renal elimination of organic anions in rats with chronic renal failure. Biochim Biophys Acta 2005; 1740: 29-37.
62. Naud J, Michaud J, Beauchemin S et al. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab Dispos 2011; 39: 1363-1369.
63. Motojima M, Hosokawa A, Yamato H et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003; 63: 1671-1680.
64. Broer S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol Rev 2008; 88: 249-286.
65. Williams RE, Major H, Lock EA et al. D-serine-induced nephrotoxicity: a HPLCTOF/ MS-based metabonomics approach. Toxicology 2005; 207: 179-190.
66. Verrey F, Ristic Z, Romeo E et al. Novel renal amino acid transporters. Annu Rev Physiol 2005; 67: 557-572.
67. Verrey F, Singer D, Ramadan T et al. Kidney amino acid transport. Pflugers Arch 2009; 458: 53-60.
68. Furmanek A, Hofsteenge J. Protein C-mannosylation: facts and questions. Acta Biochim Pol 2000; 47: 781-789.
69. Ihara Y, Manabe S, Kanda M et al. Increased expression of protein C-mannosylation in the aortic vessels of diabetic Zucker rats. Glycobiology 2005; 15: 383-392.
70. Yonemura K, Takahira R, Yonekawa O et al. The diagnostic value of serum concentrations of 2-(alpha-mannopyranosyl)-L-tryptophan for normal renal function. Kidney Int 2004; 65: 1395-1399.
71. Reuter SE, Evans AM. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet 2012; 51: 553-572.
72. Fouque D, Holt S, Guebre-Egziabher F et al. Relationship between serum carnitine, acylcarnitines, and renal function in patients with chronic renal disease. J Ren Nutr 2006; 16: 125-131.
73. Sun J, Shannon M, Ando Y et al. Serum metabolomic profiles from patients with acute kidney injury: a pilot study. J Chromatogr B 2012; 893-894: 107-113.
74. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
75. CDC/National Center for Health Statistics. Data Access-National Death Index Queried on 10 October 2010.
76. van den Berg RA, Rubingh CM, Westerhuis JA et al. Metabolomics data exploration guided by prior knowledge. Anal Chim Acta 2009; 651: 173-181.
77. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445